Skip to main content
. 2024 Aug 27;39(12):2817–2825. doi: 10.1111/jgh.16727

Figure 3.

Figure 3

Frequency of people presenting with a hepatocellular carcinoma (HCC) who had previously been enrolled in surveillance and barriers towards HCC surveillance according to disease etiology. MASLD, metabolic dysfunction‐associated steatotic liver disease.